STABL Stock Overview
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Stayble Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.25 |
| 52 Week High | kr6.42 |
| 52 Week Low | kr0.19 |
| Beta | -0.072 |
| 1 Month Change | -1.77% |
| 3 Month Change | -21.79% |
| 1 Year Change | -84.21% |
| 3 Year Change | -96.81% |
| 5 Year Change | n/a |
| Change since IPO | -97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| STABL | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.7% | -3.0% | 0.9% |
| 1Y | -84.2% | 60.0% | 10.3% |
Return vs Industry: STABL underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: STABL underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| STABL volatility | |
|---|---|
| STABL Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: STABL's share price has been volatile over the past 3 months.
Volatility Over Time: STABL's weekly volatility has decreased from 22% to 12% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Andreas Gerward | www.staybletherapeutics.se |
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ) Fundamentals Summary
| STABL fundamental statistics | |
|---|---|
| Market cap | kr7.91m |
| Earnings (TTM) | -kr23.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs STABL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STABL income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr23.74m |
| Earnings | -kr23.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.1% |
How did STABL perform over the long term?
See historical performance and comparison